We invest in visionary teams with transformative ideas.

Join Canaan's extended family.
222
companies
1,034
Jobs
Trishula Therapeutics
Trishula Therapeutics
trishulatx.com

Locations

South San Francisco, CA, USA

industry

Biotechnology · DeepTech · Health

Size

11-50 employees

Stage

Other

founded in

2020

Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with AbbVie. TTX-030 inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial step in the generation of adenosine in the tumor microenvironment. TTX-030 prevents the formation of immune-suppressive extracellular adenosine and maintains high levels of immune-activating extracellular ATP, stimulating dendritic and myeloid-derived cells necessary for both innate and adaptive immunity. Currently, TTX-030 is being studied in phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556 and NCT04306900).

Something looks off?
Open jobs at Trishula Therapeutics
Powered by Getro